Price T Rowe Associates Inc Oric Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,189,227 shares of ORIC stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,189,227
Previous 1,566,736
24.1%
Holding current value
$12.7 Million
Previous $21.5 Million
60.97%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ORIC
# of Institutions
112Shares Held
63.1MCall Options Held
0Put Options Held
0-
Nextech Invest Ag5.29MShares$56.3 Million7.05% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$51.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$46.8 Million3.41% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.14MShares$44.1 Million1.73% of portfolio
-
Viking Global Investors LP4MShares$42.6 Million0.11% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $421M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...